Madrigal Pharmaceuticals, Inc. MDGL NASDAQ

Madrigal Pharmaceuticals, Inc. (MDGL) generated $-133.46M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $390K, free cash flow was $-133.07M.

Free cash flow margin was -41.4% of revenue. Cash conversion ratio was 2.28x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (67/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 2.28x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 54/100 with 2/7 criteria passed.